Regular cancer screening program boosts survival rates for Li-Fraumeni patients
TORONTO — Keeping regular tabs on patients with a genetic disease that puts them at very high risk for developing multiple cancers over their lifetime has been shown to dramatically improve survival, researchers say.
The surveillance system, known as the Toronto Protocol, involves frequent testing of patients with Li-Fraumeni syndrome, a relatively rare condition caused by a mutated gene that is usually passed from one generation to another.
Patients with Li-Fraumeni are prone to developing a number of malignancies — from leukemia and brain tumours to bone, muscle and breast cancer — due to a mutation in a tumour-suppressor gene known as TP53.
However, a study of 89 patients published Friday in the journal Lancet Oncology found those who had regular testing to catch tumours early have a much better five-year survival rate — almost 90 per cent compared to 60 per cent — than those who did not take part in the surveillance program.


